Li et al. (2020) found through survival analysis that lung cancer patients with high P4HA1 have a poorer clinical prognosis. Targeting P4HA1 is a promising strategy for treating lung cancer. Therefore, there is an urgent need to develop small molecule inhibitors targeting lung cancer cell P4HA1. Robinson et al. discovered that the small molecule inhibitor PythiDC of P4HA1 can significantly inhibit the cell viability and invasion ability of lung cancer cells (Robinson et al., 2021). Here, P4HA1 is linked to lung cancer.